Deregulated methylation and expression of PCDHGB7 in patients with non-small cell lung cancer: a novel prognostic and immunological biomarker
BackgroundsProtocadherin gamma subfamily B, 7 (PCDHGB7), a member of the protocadherin family, plays critical roles in neuronal connections and has been implicated in female reproductive system cancers. Its function in lung cancer has not been elucidated.MethodsWe comprehensively investigated PCDHGB...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1516628/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582011195228160 |
|---|---|
| author | Yue Yuan Yue Yuan Xin Nie Jiayi Gao Jiayi Gao Yumeng Tian Yumeng Tian Liuer He Liuer He Xue Wang Ping Zhang Junling Ma Lin Li Lin Li |
| author_facet | Yue Yuan Yue Yuan Xin Nie Jiayi Gao Jiayi Gao Yumeng Tian Yumeng Tian Liuer He Liuer He Xue Wang Ping Zhang Junling Ma Lin Li Lin Li |
| author_sort | Yue Yuan |
| collection | DOAJ |
| description | BackgroundsProtocadherin gamma subfamily B, 7 (PCDHGB7), a member of the protocadherin family, plays critical roles in neuronal connections and has been implicated in female reproductive system cancers. Its function in lung cancer has not been elucidated.MethodsWe comprehensively investigated PCDHGB7 expression, prognosis, biological function, methylation patterns, and it’s relationship with immune infiltration and immunotherapy response through public datasets (HPA, TCGA, GEO, OncoDB and MEXPRESS). Two lung cancer immunotherapy cohorts from our clinical center were enrolled to detect the relationship between methylation and protein levels of PCDHGB7 in plasma and immunotherapy outcomes.ResultsPCDHGB7 expression was downregulated in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) and associated with tumor prognosis. PCDHGB7 demonstrated a positive correlation with inhibitory immune cells and a negative correlation with tumor mutational burden (TMB) and homologous recombination deficiency (HRD). The methylation level of PCDHGB7 was upregulated in tumor tissue and negatively correlated with PCDHGB7 mRNA level. In immunotherapy cohort studies, patients with higher PCDHGB7 tissue expression showed worse prognosis. Patients with PCDHGB7 hypermethylation in baseline plasma had shorter progression-free survival (PFS) and overall survival (OS), while those with early reduction of PCDHGB7 methylation had the best prognosis. Plasma PCDHGB7 protein levels could predict responses to immune checkpoint inhibitors and function as a prognostic marker for PFS.ConclusionPCDHGB7 expression and methylation are prognostic and immunological biomarkers in non-small cell lung cancer. Plasma PCDHGB7 methylation and protein levels can be used as novel biomarkers for predicting the efficacy of immunotherapy in lung cancer. |
| format | Article |
| id | doaj-art-28fb06c9afa94593b803bca2c94d0d52 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-28fb06c9afa94593b803bca2c94d0d522025-01-30T06:23:02ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011610.3389/fimmu.2025.15166281516628Deregulated methylation and expression of PCDHGB7 in patients with non-small cell lung cancer: a novel prognostic and immunological biomarkerYue Yuan0Yue Yuan1Xin Nie2Jiayi Gao3Jiayi Gao4Yumeng Tian5Yumeng Tian6Liuer He7Liuer He8Xue Wang9Ping Zhang10Junling Ma11Lin Li12Lin Li13Department of Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaBeijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaBeijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaBeijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaBeijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaDepartment of Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, ChinaBeijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaBackgroundsProtocadherin gamma subfamily B, 7 (PCDHGB7), a member of the protocadherin family, plays critical roles in neuronal connections and has been implicated in female reproductive system cancers. Its function in lung cancer has not been elucidated.MethodsWe comprehensively investigated PCDHGB7 expression, prognosis, biological function, methylation patterns, and it’s relationship with immune infiltration and immunotherapy response through public datasets (HPA, TCGA, GEO, OncoDB and MEXPRESS). Two lung cancer immunotherapy cohorts from our clinical center were enrolled to detect the relationship between methylation and protein levels of PCDHGB7 in plasma and immunotherapy outcomes.ResultsPCDHGB7 expression was downregulated in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) and associated with tumor prognosis. PCDHGB7 demonstrated a positive correlation with inhibitory immune cells and a negative correlation with tumor mutational burden (TMB) and homologous recombination deficiency (HRD). The methylation level of PCDHGB7 was upregulated in tumor tissue and negatively correlated with PCDHGB7 mRNA level. In immunotherapy cohort studies, patients with higher PCDHGB7 tissue expression showed worse prognosis. Patients with PCDHGB7 hypermethylation in baseline plasma had shorter progression-free survival (PFS) and overall survival (OS), while those with early reduction of PCDHGB7 methylation had the best prognosis. Plasma PCDHGB7 protein levels could predict responses to immune checkpoint inhibitors and function as a prognostic marker for PFS.ConclusionPCDHGB7 expression and methylation are prognostic and immunological biomarkers in non-small cell lung cancer. Plasma PCDHGB7 methylation and protein levels can be used as novel biomarkers for predicting the efficacy of immunotherapy in lung cancer.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1516628/fullPCDHGB7methylationlung cancerimmunotherapybiomarkers |
| spellingShingle | Yue Yuan Yue Yuan Xin Nie Jiayi Gao Jiayi Gao Yumeng Tian Yumeng Tian Liuer He Liuer He Xue Wang Ping Zhang Junling Ma Lin Li Lin Li Deregulated methylation and expression of PCDHGB7 in patients with non-small cell lung cancer: a novel prognostic and immunological biomarker Frontiers in Immunology PCDHGB7 methylation lung cancer immunotherapy biomarkers |
| title | Deregulated methylation and expression of PCDHGB7 in patients with non-small cell lung cancer: a novel prognostic and immunological biomarker |
| title_full | Deregulated methylation and expression of PCDHGB7 in patients with non-small cell lung cancer: a novel prognostic and immunological biomarker |
| title_fullStr | Deregulated methylation and expression of PCDHGB7 in patients with non-small cell lung cancer: a novel prognostic and immunological biomarker |
| title_full_unstemmed | Deregulated methylation and expression of PCDHGB7 in patients with non-small cell lung cancer: a novel prognostic and immunological biomarker |
| title_short | Deregulated methylation and expression of PCDHGB7 in patients with non-small cell lung cancer: a novel prognostic and immunological biomarker |
| title_sort | deregulated methylation and expression of pcdhgb7 in patients with non small cell lung cancer a novel prognostic and immunological biomarker |
| topic | PCDHGB7 methylation lung cancer immunotherapy biomarkers |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1516628/full |
| work_keys_str_mv | AT yueyuan deregulatedmethylationandexpressionofpcdhgb7inpatientswithnonsmallcelllungcanceranovelprognosticandimmunologicalbiomarker AT yueyuan deregulatedmethylationandexpressionofpcdhgb7inpatientswithnonsmallcelllungcanceranovelprognosticandimmunologicalbiomarker AT xinnie deregulatedmethylationandexpressionofpcdhgb7inpatientswithnonsmallcelllungcanceranovelprognosticandimmunologicalbiomarker AT jiayigao deregulatedmethylationandexpressionofpcdhgb7inpatientswithnonsmallcelllungcanceranovelprognosticandimmunologicalbiomarker AT jiayigao deregulatedmethylationandexpressionofpcdhgb7inpatientswithnonsmallcelllungcanceranovelprognosticandimmunologicalbiomarker AT yumengtian deregulatedmethylationandexpressionofpcdhgb7inpatientswithnonsmallcelllungcanceranovelprognosticandimmunologicalbiomarker AT yumengtian deregulatedmethylationandexpressionofpcdhgb7inpatientswithnonsmallcelllungcanceranovelprognosticandimmunologicalbiomarker AT liuerhe deregulatedmethylationandexpressionofpcdhgb7inpatientswithnonsmallcelllungcanceranovelprognosticandimmunologicalbiomarker AT liuerhe deregulatedmethylationandexpressionofpcdhgb7inpatientswithnonsmallcelllungcanceranovelprognosticandimmunologicalbiomarker AT xuewang deregulatedmethylationandexpressionofpcdhgb7inpatientswithnonsmallcelllungcanceranovelprognosticandimmunologicalbiomarker AT pingzhang deregulatedmethylationandexpressionofpcdhgb7inpatientswithnonsmallcelllungcanceranovelprognosticandimmunologicalbiomarker AT junlingma deregulatedmethylationandexpressionofpcdhgb7inpatientswithnonsmallcelllungcanceranovelprognosticandimmunologicalbiomarker AT linli deregulatedmethylationandexpressionofpcdhgb7inpatientswithnonsmallcelllungcanceranovelprognosticandimmunologicalbiomarker AT linli deregulatedmethylationandexpressionofpcdhgb7inpatientswithnonsmallcelllungcanceranovelprognosticandimmunologicalbiomarker |